Romn A, Martnez-Prez O

Tabla 1. Categoras de Organizacin mundial de la salud de Criterios

mdicos para elegir mtodos contraceptivos

Figura 1: Mecanismos propagacion EIP.

Tabla 2. Grmenes aislados en EIP

Figura 2: evolucion hallazgos ecograficos.

Figura 3: Abceso tubarico activo.

 Figura 5: Episalpinx.

Figura 4: Hidrosalpinx.

Figura 6: Abceso tuboovrico 2. Figura 7: Abceso tuboovrico 2.

Figura 8: Abceso tuboovrico. Figura 9: Pseudotabiquehidosalpinx.

Figura 10: Hidrosalpinx Septo incompleto. Figura 11: Mucosa tubarica resros rueda dentada.
Figura 12: Adherencias.
Tabla 3. Pautas de tratamiento oral Tabla 4. Pautas de tratamiento intravenoso

- American College of Obstetricians and Gynocologists. Gui-
delines for Womens Health care. American College of Obs-
tetricians and Gynocologists, Washington, DC 1996.
- Anshu P. Mohllaje, Kathry M. Curtis, Herbert B. Peterson.
Does insertion and use of an intrauterine device increase the
risk of pelvic inflammatory disease among woman with se-
xually transmitted infection? A systematic review. Contracep-
tion. 73; 145-153. 2006.
- Bruce G. Trigg, Peter R. Kerndt, Getahun Aynalem. Sexually
Transmitted Infections and Pelvic Inflammatory disease in
Women. Med Clin N Am. 92;1083-1113. 2008.
- Gjelland, K; Ekerhovd, E; Granberg, S. Transvaginal ultra-
sound-guided aspiration for treatment of tubo-ovarian abs-
cess:a study of 302 cases. Am J Obstet Gynecol. 193:1323.
2005.
- Grimes ,DA. Intrauterine device and upper-genital-tract infec-
tion. Lancet. 356:1013. 2000.
- Grimes, DA; Schultz, FK. Antibiotic profilaxis for intrauterine
contraceptive device insertion. Cochrane Database of Syste-
matic Reviews 2008.
- Masters.T, Everett.S. Intrauterine and barrier contraception (a
practical review of recent developments) Current Obstetrics
and Gynaecology. 15, 31-37. 2005.
- Ness, RB; Soper, DE; Holley, RL; et al.Effectiveness of inpatient
and outpatient treatment strategies for women with pelvic in-
flammatory disease evaluation and clinical health (PEACH) ran-
domized trial. Am J Obstet Gynecol. 186:929. 2002.
- Peipert, JF; Ness ,RB; Blume, J et al. Clinical predictors
of endometritis in women with symptoms and signs of pel-
vic inflammatory disease. Am J Obstet Gynecol. 100:456.
2002.
- Protopapas, AG; Diakomanolis, ES; Milingos, SD, et al. Tubo-
ovarian abscess in postmenopausal women: gynecol malig-
nancy until proven otherwise?. Eur J Obstet Gynecol Reprod
Biol. 114:203. 2004.
- Ross,J; Stewart, P. Management of Acute Pelvic Inflammatory
Disease. Royal College of Obstetricians and Gynaecologists.
- Savaris, RF; Teixeira, LM; Torres, TG; et al. Comparing cef-
triaxone plus azitromycin or Doxycicline for pelvic inflamma-
tory disease: Arandomized controlled trial. Obstet Gynecol.
110:53. 2007.
- Stacey, CM; Munday, PE; Taylor-Robinson, D, et al. A longi-
tudinal study of pelvic inflammatory disease. Br J Obset
Gynaecol. 99: 994. 1992.
- U.S. Department of Health and Human Services Centers for
Disease Control and Prevention. Sexually Transmitted Disease
Surveillance 2006 y 2007.
- Washington, AE, Katz, P. Cost of and payment source for pel-
vic inflammatory disease. JAMA. 266: 2565. 1991.
- Workowski, KA, Berman SM. Sexually transmitted diseases
treatment guidelines, 2006. MMWR Recomm Rep. 55:1.
2006.